AMGN or NVS or PFE

Key Takeaways

• AMGN delivered 10% revenue growth in 2025, powered by 14 blockbuster products and a fast-expanding cardiovascular and inflammation portfolio, though biosimilar headwinds are gathering.
• NVS posted an 8% sales increase and expanded its core operating margin to 40.1% in 2025, but faces its largest-ever patent expiry cycle in 2026, creating a transitional earnings profile.
• PFE reported $62.6 billion in 2025 revenue with 6% operational growth from its non-COVID portfolio, yet declining COVID sales and upcoming loss-of-exclusivity events are compressing the near-term outlook.
• All three companies are investing heavily in next-generation pipelines — obesity, oncology, and rare disease — but they sit at markedly different stages of the innovation cycle.
• Relative positioning favors AMGN for momentum, NVS for margin quality, and PFE for deep-value income exposure, reflecting three distinct risk-reward profiles in the large-cap pharmaceutical space.

Introduction

Large-cap pharmaceutical stocks often attract investors seeking a blend of defensive stability, dividend income, and exposure to medical innovation. Amgen (AMGN), Novartis (NVS), and Pfizer (PFE) all fit that description, yet their recent trajectories have diverged meaningfully. One is riding a wave of product-launch momentum, another is navigating a historic patent cliff with disciplined margin management, and the third is undertaking a broad strategic reset after a pandemic-era revenue surge subsided. This comparison examines how these three pharmaceutical giants stack up across growth, valuation, pipeline quality, and market sentiment, offering a clear, data-driven reference for traders and investors evaluating relative positioning in the sector.

AMGN Overview and Recent Performance

Amgen (AMGN), headquartered in Thousand Oaks, California, is one of the world's largest independent biotechnology companies. Its portfolio spans cardiovascular disease, oncology, inflammation, and rare disease, with 14 products generating more than $1 billion in annual sales by the end of 2025. In recent market activity, Amgen has drawn consistent investor attention for its ability to sustain double-digit volume growth across a diversified product base. Full-year 2025 revenues reached $36.8 billion, representing a 10% increase year over year, while non-GAAP (non-GAAP stands for non-Generally Accepted Accounting Principles, meaning earnings adjusted for one-time and non-cash items) earnings per share rose to $21.84. Key growth drivers — including the cholesterol-lowering therapy Repatha (up 36%), the asthma biologic Tezspire (up 52%), and the osteoporosis treatment EVENITY (up 34%) — have reinforced confidence that the company can offset erosion from biosimilar competition facing legacy products such as Prolia. The weight-management candidate MariTide, now in multiple Phase 3 studies, adds a significant optionality catalyst. However, headwinds include a $1.2 billion intangible asset impairment tied to Otezla following its selection for Medicare price negotiations under the Inflation Reduction Act, as well as caution around 2026 guidance implying revenue growth of 1% to 4%.

NVS Overview and Recent Performance

Novartis (NVS), based in Basel, Switzerland, operates as a pure-play innovative medicines company following the 2023 spin-off of its Sandoz generics division. The firm is concentrated in four therapeutic areas: cardiovascular-renal-metabolic, immunology, neuroscience, and oncology. Full-year 2025 net sales rose 8% to $54.5 billion, while core operating income advanced 14% at constant currencies, pushing the core operating margin to 40.1%. This margin expansion — a milestone the company had targeted for years — reflects the growing contribution of high-margin next-generation drugs. Kisqali (breast cancer) surged 57%, Kesimpta (multiple sclerosis) grew 44%, Pluvicto (prostate cancer radioligand therapy) climbed 42%, and Scemblix (chronic myeloid leukemia) soared 85%. Free cash flow reached $17.6 billion, supporting a proposed 5.7% dividend increase. Yet the company is now entering what management has described as the largest patent expiry in its history, centered on the heart failure blockbuster Entresto. In Q4 2025, Entresto sales dropped 45% year over year due to U.S. generic competition. The planned $12 billion acquisition of Avidity Biosciences, which brings a platform of RNA-based neuromuscular disease therapies, signals ambitious pipeline investment, but 2026 guidance for low single-digit sales growth and a modest decline in core operating income reflects the transitional nature of the current period.

PFE Overview and Recent Performance

Pfizer (PFE), headquartered in New York City, is one of the largest pharmaceutical companies by revenue globally. Its 2025 results captured a business in the midst of a pivot: total revenues reached $62.6 billion, a 2% operational decline from the prior year, but stripping out COVID-19 products (Paxlovid and Comirnaty) revealed 6% operational growth from the non-COVID portfolio. Adjusted diluted earnings per share came in at $3.22, up from $3.11 in 2024, as cost-savings initiatives and margin discipline took hold. Recently launched and acquired products — spanning oncology, vaccines, and specialty care — generated $10.2 billion in revenue, rising 14% operationally. The company returned $9.8 billion to shareholders through dividends and invested $10.4 billion in internal R&D. Still, the stock has faced persistent pressure. COVID product revenues fell approximately 40% year over year in Q4 2025, and 2026 guidance points to further compression, with total revenue forecast at $59.5 billion to $62.5 billion and adjusted EPS of $2.80 to $3.00. Approximately $1.5 billion in revenue is expected to be lost from products facing generic entry. A $4.4 billion non-cash impairment charge in Q4, tied to deprioritized pipeline and in-line assets, underscored the portfolio reprioritization underway. On the catalyst front, the obesity pipeline acquired through Metsera — with ten pivotal trials planned in 2026 — represents a high-stakes growth bet.

Trending AI Robots

In an environment where pharmaceutical stocks are driven by complex, multi-variable forces — pipeline readouts, patent cliffs, regulatory decisions, and macroeconomic sentiment — many traders are turning to AI-driven tools to help filter the noise. Tickeron's Trending AI Robots page curates a selection of the platform's top-performing algorithmic trading bots, chosen for their adaptability to current market conditions. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, with performance statistics that can include annualized returns, trade success rates, and Sharpe ratios. Each bot operates with its own distinct trading style, strategy, timeframe, and set of monitored tickers — ranging from short-term swing trading models to longer-duration trend-following algorithms. The Trending AI Robots section narrows this universe to the bots that have demonstrated the strongest alignment with prevailing market dynamics, offering traders a data-driven starting point. Explore the Trending AI Robots page to see which strategies are currently leading.

Head-to-Head Comparison

When assessing AMGN, NVS, and PFE side by side, several contrasts emerge. From a revenue growth perspective, AMGN leads with 10% growth in 2025, driven by high-volume demand across its biologics portfolio and minimal exposure to the acute generic erosion plaguing peers. NVS posted a healthy 8% gain but is now facing a steep patent cliff that will likely compress top-line growth in 2026. PFE remains the revenue giant at $62.6 billion, but its top line is shrinking as COVID-related products decline and loss-of-exclusivity events approach. On profitability and margin quality, NVS stands out with a 40.1% core operating margin — the highest of the three — reflecting a tightly focused innovative medicines portfolio. AMGN operates at a non-GAAP margin of approximately 46%, though its GAAP (Generally Accepted Accounting Principles, referring to standard accounting rules) margin is lower, and its R&D spending rose 22% in 2025. PFE carries the lowest adjusted gross margin at around 76% for the full year, with quarterly volatility driven by product mix shifts. In terms of dividend appeal, PFE offers the highest yield at roughly 6.9%, reflecting price compression and a commitment to returning capital. AMGN offers approximately 3%, with 14 consecutive years of dividend increases. NVS sits between them, having proposed a 5.7% dividend increase for 2025. Pipeline positioning also diverges. AMGN has the obesity candidate MariTide as a potentially transformative asset, while PFE is placing a major bet on its Metsera-derived obesity pipeline with ten pivotal trials in 2026. NVS is differentiating through radioligand therapy platforms, gene therapy, and the Avidity RNA acquisition, targeting neuromuscular diseases. Risk factors vary: NVS faces the most immediate patent-expiry pressure, PFE contends with COVID revenue normalization and regulatory pricing uncertainty, and AMGN must navigate biosimilar erosion for Prolia while managing IRA-related pricing impacts on Otezla.

Tickeron AI Verdict

Based on observable trend consistency, earnings momentum, and relative resilience to near-term headwinds, Tickeron's AI-driven analytical framework would likely tilt in favor of AMGN among these three names. The company enters the current period with the cleanest growth trajectory — 10% revenue expansion, multiple products in double-digit growth phases, and pipeline catalysts in obesity and cardiovascular disease that are yet to be fully priced. NVS demonstrates superior margin quality and free cash flow generation, but its 2026 patent-cliff narrative introduces a transitional uncertainty that quantitative models tend to penalize in the near term. PFE offers the most compelling income profile and a deep pipeline, yet the combination of declining COVID revenues, loss-of-exclusivity headwinds, and compressed earnings guidance creates a more complex turnaround case that trend-following algorithms would likely approach with caution. In probabilistic terms, AMGN currently presents the most favorable alignment of positive momentum, manageable risk factors, and visible catalysts — though the relative ranking among these three large-cap pharmaceutical stocks could shift as pipeline milestones and macro conditions evolve.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations